AIIMS Delhi Conducts India's First Advanced Brain Stent Trial

New Delhi- AIIMS Delhi has achieved a milestone in stroke care by conducting the country's first dedicated clinical trial of a cutting-edge and advanced brain stent made for treating severe strokes.

The GRASSROOT trial, which evaluated the Supernova stent (Gravity Medical Technology), has found excellent safety and efficacy outcomes in the treatment of severe strokes, officials said.

The results were published in the 'Journal of Neurointerventional Surgery' (JNIS), part of the prestigious British Medical Journal group.

AIIMS Delhi was the national coordinating centre and the lead enrolling site for the GRASSROOT trial – India's first clinical trial of a new and advanced stroke treatment device, the Supernova stent, the officials said.

“This trial is a turning point for stroke treatment in India,” Dr Shailesh B Gaikwad, professor and head, Department of Neuroimaging and Interventional Neuroradiology, AIIMS Delhi, and national principal investigator of the GRASSROOT trial, said.

According to the JNIS, the GRASSROOT trial evaluating the Supernova stent has found excellent safety and efficacy outcomes in the treatment of severe strokes.

Earlier this year, data from the GRASSROOT trial were accepted by the Central Drugs Standard Control Organisation (CDSCO) and the Supernova stent-retriever was approved for routine use in India.

“This is the nation's first stroke device cleared based on a domestic clinical trial. The approval follows the GRASSROOT India trial, which confirmed the device's safety and efficacy in treating life-threatening strokes,” AIIMS said in a statement.

“Conducted across eight centres, the trial marks a milestone for the Make-in-India initiative and positions India as a global player in advanced stroke care,” it said.

MENAFN14122025000215011059ID1110477335